ProfileGDS5678 / 1451691_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 70% 69% 70% 70% 69% 71% 70% 70% 78% 71% 62% 70% 70% 70% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.3777570
GSM967853U87-EV human glioblastoma xenograft - Control 24.2646869
GSM967854U87-EV human glioblastoma xenograft - Control 34.3601670
GSM967855U87-EV human glioblastoma xenograft - Control 44.412370
GSM967856U87-EV human glioblastoma xenograft - Control 54.2165569
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.4008471
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.352270
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.3354270
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.4093778
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.451771
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7228962
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.3985770
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.3582370
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.3491370